Navigation Links
BioVex Announces Publication of Phase 2 Melanoma Results With OncoVEX (GM-CSF) in the Journal of Clinical Oncology
Date:11/2/2009

tatic disease progressing at enrollment have been declared disease free. BioVex believes OncoVEX (GM-CSF) has the potential to become a leading standard of care in the treatment of many solid tumors based on the strength of clinical data so far generated coupled with the relatively benign side effect profile noted to date. Previous clinical trials have enrolled patients with breast cancer, melanoma, head and neck cancer and pancreatic cancer, with indications of clinical activity being observed in each. The Company recently commenced a Phase 3 study in metastatic melanoma following the achievement of an unprecedented proportion of durable complete remissions in a Phase 2 study using OncoVEX (GM-CSF) as a stand alone therapy. An overview of the Phase 2 melanoma results is available on the BioVex website. In September 2009 the Company received approval under the SPA procedure in relation to a second Phase 3 study in head and neck cancer.

About BioVex

BioVex is a privately held biotechnology company based in Woburn, MA where it also has an operational launch grade manufacturing facility. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

In addition to OncoVEX, the Company has a second development program, ImmunoVEX (HSV2), a vaccine for genital herpes that provides complete protection in animal models of the disease. The vaccine has been authorized to commence clinical testing in the United Kingdom.

For further information, please go to www.biovex.com.

SOURCE BioVex Inc


'/>"/>
SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
2. BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; A Vaccine Candidate for Genital Herpes
3. BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
4. BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
5. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
6. PDL BioPharma Announces Closing of $300,000,000 Securitization Transaction
7. Arcadia Resources Announces Webcast of Its Fiscal 2010 Second Quarter Conference Call
8. ATS Medical Announces First in World Human Robotic Endoscopic Aortic Valve Replacement
9. Nuevolution Announces Receipt of Milestone Payment From Merck & Co., Inc.
10. Stryker Announces Change in Chairman of the Board of Directors
11. Cardica Announces Fiscal 2010 First Quarter Financial Results and Business Progress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 Astellas announced ... of Business Communications & Advocacy, Urology in the ... Communications & Advocacy Margaret Long. In this role, Noland ... urology to patient and advocacy organizations, as well ... key strategic initiatives. Noland,s appointment is the latest ...
(Date:9/16/2014)... YORK , Sept. 16, 2014 This report ... by the following Product Segments: Devices, and Medication. The report ... , Japan , Europe ... America , and Rest of World. Annual estimates and ... a seven-year historic analysis is provided for these markets. Market ...
(Date:9/16/2014)... Wash. , Sept. 16, 2014 /PRNewswire/ ... a late stage development company engaged primarily ... medical isotopes for diagnostic and therapeutic applications, ... for technology related to its brachytherapy products.  ... arise from its license from Battelle, under ...
Breaking Medicine Technology:Christy Noland to Lead Urology Advocacy and Communications for Astellas 2Global Foot Care Products Industry 2Global Foot Care Products Industry 3Global Foot Care Products Industry 4Global Foot Care Products Industry 5Global Foot Care Products Industry 6Global Foot Care Products Industry 7Global Foot Care Products Industry 8Global Foot Care Products Industry 9Global Foot Care Products Industry 10Global Foot Care Products Industry 11Global Foot Care Products Industry 12Global Foot Care Products Industry 13Global Foot Care Products Industry 14Global Foot Care Products Industry 15Global Foot Care Products Industry 16Global Foot Care Products Industry 17Global Foot Care Products Industry 18Global Foot Care Products Industry 19Global Foot Care Products Industry 20Global Foot Care Products Industry 21Global Foot Care Products Industry 22Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4
... loss of Arf gene in presence of BCR-ABL ... of the bone,marrow, helping cells develop immunity to ... 29 Results of a study,by investigators at ... why the drug imatinib (Gleevec(TM)), which has revolutionized,the ...
... from Roche-, MONTVALE, N.J., Aug. 29 ... the dosing of the,first subject in the single ... program of R4996/MEM 63908, a partial agonist of ... could be beneficial in,the treatment of Alzheimer,s disease ...
Cached Medicine Technology:St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia 2Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908 2Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908 3
(Date:9/16/2014)... Kathleen Doheny HealthDay Reporter ... urine test can routinely spot human papillomavirus (HPV), which is ... found. "Our study shows that testing urine for HPV ... the cervix for HPV," said lead researcher Dr. Neha Pathak. ... fellow at Queen Mary University of London, England. The ...
(Date:9/16/2014)... 2014 These new programs allow those who ... receive up to $10,000 in a 0% interest free, 2nd ... other state and federal programs, are listed on their private ... until you sell or move out of the property. The ... loan. There are no monthly payments paid by the Borrower. ...
(Date:9/16/2014)... A new study found that fractional flow ... true coronary bifurcation lesions yields similar outcomes to ... trial is the first study to compare FFR-guided ... today at the 26th annual Transcatheter Cardiovascular Therapeutics ... Foundation (CRF), TCT is the world,s premier educational ...
(Date:9/16/2014)... Washington, DC (PRWEB) September 16, 2014 ... could potentially yield hundreds of billions of dollars in ... 2007 report by the Commonwealth Fund. To help spur ... is seeking up to 10 collaborative groups from across ... 1.0 ( http://bit.ly/1wo4gsa ) - a handbook designed ...
(Date:9/16/2014)... Angeles, CA (PRWEB) September 16, 2014 ... League of United Latin American Citizens (LULAC) will host ... LULAC’s Feria de Salud will feature free health screenings ... Other free testing includes glucose and cholesterol levels as ... will be available for children under 6 years old ...
Breaking Medicine News(10 mins):Health News:Urine Test for HPV Works Well, Analysis Finds 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 3Health News:Results of DKCRUSH-VI trial reported at TCT 2014 2Health News:NQF Seeks Field Testing Groups for Population Health Guide 2Health News:NQF Seeks Field Testing Groups for Population Health Guide 3Health News:LULAC Hosts Second Annual Latinos Living Healthy Feria de Salud in Los Angeles 2
... ... is giving away 10,000 free business card pens. , ... (PRWEB) December 2, 2009 -- National Pen ( www.pens.com ), a ... pens. , , , , ,“We have a new way to promote business that no ...
... ... direct microwave signal transmissions away from users will be available in early 2010 from ... ... signal transmissions away from users will be available in early 2010 from Aerius International ...
... ... and walkers from Las Vegas and around the country will cross the ... by Zappos.com, raising over $3.2 million for the Crohn,s & Colitis Foundation ... charity of the race, the funds will go toward research, education, and ...
... 2 The American Health Information Management Association,s Board ... be the next chief executive of the 55,000-member health ... information experience includes academia, systems management, strategic expertise, governance ... scheduled to take office January 13, 2010. , "Dr. ...
... , , WASHINGTON, Dec. ... 2 in their campaign against the U.S. House bill,s pro-life ... CEO Charmaine Yoest released this statement in response to the ... "By confusing abortion with health care, the feminist groups and ...
... Washington Post Highlights Dangers , WASHINGTON, ... way, many medical treatments and preventative measures we take for granted may ... to bear on the debate over healthcare reform has been widely reported. ... likely impact if that pressure to influence healthcare policy is not curtailed. ...
Cached Medicine News:Health News:National Pen Giving Away 10,000 Business Card Pens 2Health News:New AERIUS Cell Phones Direct Microwave Signals Away from Users 2Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 2Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 3Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 4Health News:Dr. Alan F. Dowling Named AHIMA's Next Chief Executive Officer 2Health News:Everybody's Healthcare Is Threatened by Catholic Bishops' Interference 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: